Literature DB >> 24369271

Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin.

Lars P Kristensen1, Martin R Larsen2, Hans Mickley3, Lotte Saaby4, Axel C P Diederichsen3, Jess Lambrechtsen5, Lars M Rasmussen6, Martin Overgaard1.   

Abstract

Atherosclerosis is a chronic disease of the arterial wall that is recognized as the leading cause of mortality and morbidity worldwide. There is an eminent need for better biomarkers that can aid in patient care before the onset of the first cardiovascular event. We used quantitative proteomics to identify proteins with altered concentrations in plasma samples from four groups: 1) Individuals without cardiovascular symptoms and without the presence of coronary calcium, 2) individuals without cardiovascular symptoms, but with high amounts of coronary calcium, 3) individuals operated because of atherosclerotic diseases, and 4) individuals with an acute coronary syndrome. Immunoassays and SRM-MS were used for single patient verification of candidate proteins. Proteins involved in cardiovascular diseases i.e. serum amyloid protein A (SAA), C-reactive protein (CRP), and apolipoprotein(a) [apo(a)] displayed an increased expression profile from groups 1 to 4. The top-most elevated protein, vinculin (Vcl) displayed a similar profile. Immunoassays confirmed the expression profile of apo(a) and CRP. A 5-plex SRM-MS assay for Vcl, SAA, CRP, apo(a) and thrombospondin-4 (TSP-4) was developed for multiplex verification in all 120 individual samples. The 5-plex SRM assay confirmed a statistically significant up-regulation of Vcl in the acute coronary syndrome group. BIOLOGICAL SIGNIFICANCE: The aim of this study was to identify new candidate plasma markers of atherosclerosis manifestations, which may develop into screening-, diagnostic- or monitoring biomarkers for risk stratification of cardiovascular disease (CVD). At present no studies have elucidated the proteomic changes that occur along with several stages and manifestations of atherosclerotic disease. By using 4-plex iTRAQ, we identified and quantified proteins with altered concentrations in pooled plasma samples from 120 individuals from four middle-aged groups. Proteins involved in cardiovascular diseases i.e. serum amyloid protein A (SAA), C-reactive protein (CRP), and apolipoprotein(a) [apo(a)] displayed an increased expression profile along with increased manifestations of CVD. A novel candidate marker was identified as vinculin (Vcl), a multi-protein linker that connects cell-matrix adhesions and cell-cell adhesions to the actin-based cytoskeleton. Immuno- and SRM-assays were used for single patient validation of candidate proteins. While further studies needs to address the role of Vcl in the development of atherosclerosis, the combined data provided in this report offers a catalog of the proteomic changes that occurs in plasma over several stages and manifestations of atherosclerotic disease.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Immunoassay; Plasma biomarker; Proteomics; Selected-reaction-monitoring; Vinculin

Mesh:

Substances:

Year:  2013        PMID: 24369271     DOI: 10.1016/j.jprot.2013.12.011

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  11 in total

1.  Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes.

Authors:  Helen C Looker; Marco Colombo; Felix Agakov; Tanja Zeller; Leif Groop; Barbara Thorand; Colin N Palmer; Anders Hamsten; Ulf de Faire; Everson Nogoceke; Shona J Livingstone; Veikko Salomaa; Karin Leander; Nicola Barbarini; Riccardo Bellazzi; Natalie van Zuydam; Paul M McKeigue; Helen M Colhoun
Journal:  Diabetologia       Date:  2015-03-05       Impact factor: 10.122

Review 2.  Unbiased and targeted mass spectrometry for the HDL proteome.

Authors:  Sasha A Singh; Masanori Aikawa
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

Review 3.  Quantitative proteomics in cardiovascular research: global and targeted strategies.

Authors:  Xiaomeng Shen; Rebeccah Young; John M Canty; Jun Qu
Journal:  Proteomics Clin Appl       Date:  2014-07-14       Impact factor: 3.494

4.  Proteomics analysis reveals a potential new target protein for the lipid-lowering effect of Berberine8998.

Authors:  Cheng-Yin Yu; Gang-Yi Liu; Xiao-Hui Liu; Yu-Zhou Gui; Hai-Ming Liu; Hong-Chao Zheng; Darek C Gorecki; Asmita V Patel; Chen Yu; Yi-Ping Wang
Journal:  Acta Pharmacol Sin       Date:  2018-04-12       Impact factor: 6.150

5.  High Plasma Levels of Soluble Talin-1 in Patients with Coronary Artery Disease.

Authors:  Masayuki Aoyama; Yoshimi Kishimoto; Emi Saita; Yukinori Ikegami; Reiko Ohmori; Masato Nakamura; Kazuo Kondo; Yukihiko Momiyama
Journal:  Dis Markers       Date:  2020-05-29       Impact factor: 3.434

6.  Proteomic Signatures of Lifestyle Risk Factors for Cardiovascular Disease: A Cross-Sectional Analysis of the Plasma Proteome in the Framingham Heart Study.

Authors:  Laura Corlin; Chunyu Liu; Honghuang Lin; Dominick Leone; Qiong Yang; Debby Ngo; Daniel Levy; L Adrienne Cupples; Robert E Gerszten; Martin G Larson; Ramachandran S Vasan
Journal:  J Am Heart Assoc       Date:  2020-12-29       Impact factor: 5.501

Review 7.  Cardiovascular biomarkers in body fluids: progress and prospects in optical sensors.

Authors:  Reena V John; Tom Devasiya; Nidheesh V R; Sphurti Adigal; Jijo Lukose; V B Kartha; Santhosh Chidangil
Journal:  Biophys Rev       Date:  2022-08-18

8.  Serum Proteomic Profiling to Identify Biomarkers of Premature Carotid Atherosclerosis.

Authors:  Santosh D Bhosale; Robert Moulder; Mikko S Venäläinen; Juhani S Koskinen; Niina Pitkänen; Markus T Juonala; Mika A P Kähönen; Terho J Lehtimäki; Jorma S A Viikari; Laura L Elo; David R Goodlett; Riitta Lahesmaa; Olli T Raitakari
Journal:  Sci Rep       Date:  2018-06-15       Impact factor: 4.379

9.  Inverse changes in plasma tetranectin and titin levels in patients with type 2 diabetes mellitus: a potential predictor of acute myocardial infarction?

Authors:  Mohd Aizat Abdul Rahim; Zubaidah Haji Abdul Rahim; Wan Azman Wan Ahmad; Marina Mohd Bakri; Muhammad Dzafir Ismail; Onn Haji Hashim
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

Review 10.  Recent Developments in Clinical Plasma Proteomics-Applied to Cardiovascular Research.

Authors:  Nicolai Bjødstrup Palstrøm; Rune Matthiesen; Lars Melholt Rasmussen; Hans Christian Beck
Journal:  Biomedicines       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.